LENZ Therapeutics, Inc.

NASDAQ:LENZ

Biotechnology

Healthcare
$3.21 -6.62%

-$0.42 today

Market cap
$100.86M
Beta
1.47
P/E (TTM)
-1.7
EPS (TTM)
-$3.48
52W Low $5.85High $50.40

Volume 0.62M

Average 0.89M

LENZ EPS (Basic)

Net income attributable to common shareholders divided by the weighted average basic shares outstanding.

LENZ Therapeutics, Inc.NASDAQ: LENZ

EPS (Basic) · Q1 FY2026 · quarter ended Mar 2026

EPS (Basic) remains negative

Q1 FY2026 EPS (Basic) was -$1.32, compared with -$0.53 a year earlier. Trailing-twelve-month EPS (Basic) was -$3.6.

Context

  • EPS (Basic) grew in size in 2 of the last 3 fiscal years.

What to watch

Whether EPS (Basic) reaches the consensus estimate from 6 analysts of -$4.12 (-44.6%) for the fiscal year ending Dec 2026, a slowdown from the -21.8% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-$1.32-13.8% QoQ
Last fiscal yearDec 2025
-$2.85-21.8% YoY
LTMMar 2026
-$3.6-103.4% YoY
EPS (Basic) past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-149.1%-98.2%+50.9 pp
1 year-21.8%-44.6%-22.9 pp
3-year CAGR———
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EPS (Basic) history

USD · from the income statement

Latest · FY2025
(2.85) USD
Year-over-year change
-21.8%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EPS (Basic) vs competitors

How LENZ compares with its peers on the latest reported figures

  • Peers report in different currencies, so EPS (Basic) is compared through growth and rates rather than absolute size.
  • Its year-over-year change of -103.4% is the 10th highest of 11, against a peer median of +26.4%.
LENZ Competitors
EPS (Basic) for LENZ and competitors
Company Period LTM YoY 3-year CAGR
ABUSArbutus Biopharma CorporationLTM Mar 2026$0.83 USD+304.6%—
GERNGeron CorporationLTM Mar 2026-$0.1 USD+50.1%—
NBTXNanobiotix S.A.FY2025-€0.5 EUR+65.3%—
MRVIMaravai LifeSciences Holdings, Inc.LTM Jun 2026-$0.54 USD+60.6%—
SVRASavara Inc.LTM Mar 2026-$0.56 USD-14.3%—
RZLTRezolute, Inc.LTM Mar 2026-$0.82 USD+29.3%—
GHRSGH Research PLCLTM Mar 2026-$0.92 USD-16.5%—
PRMEPrime Medicine, Inc.LTM Mar 2026-$1.27 USD+23.5%—
SPRYARS Pharmaceuticals, Inc.LTM Mar 2026-$2.01 USD-1082.4%—
TYRATyra Biosciences, Inc.LTM Mar 2026-$2.18 USD-33.7%—
LENZLENZ Therapeutics, Inc.LTM Mar 2026-$3.6 USD-103.4%—
Peer median (excluding LENZ) —+26.4%—

Competitors are the stored peer set for LENZ. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue015M0019.09M
Cost of Revenue734K0058K705K
Gross Profit(734K)15M0(58K)18.38M
Gross Margin—100.0%——96.3%
Research & Development37.93M21.13M59.5M29.8M18.67M
Selling, General & Admin21.78M4.36M12.93M28.75M90.85M
Operating Expenses59.71M25.48M72.43M58.55M109.52M
Depreciation & Amortization734K8K15K58K287K
EBITDA(70.03M)(10.46M)(70.13M)(49.71M)(81.34M)
EBITDA Margin—-69.7%——-426.1%
Operating Income(60.44M)(10.48M)(72.43M)(58.61M)(91.14M)
Operating Margin—-69.9%——-477.5%
Interest Income002.19M8.55M9.76M
Interest Expense00000
Other Income / Expenses(10.32M)19K2.28M8.84M9.51M
Income Before Tax(70.76M)(10.46M)(70.15M)(49.77M)(81.63M)
Pre-Tax Margin—-69.8%——-427.6%
Income Tax Expense0347K(179K)1K502K
Net Income(70.76M)(10.81M)(69.97M)(49.77M)(82.13M)
Net Margin—-72.1%——-430.3%
EPS (Basic)(8.54)(12.89)(15.30)(2.34)(2.85)
EPS (Diluted)(8.54)(12.89)(15.30)(2.34)(2.85)
Weighted Avg Shares8.29M7.84M8.15M21.28M28.81M
Weighted Avg Shares (Diluted)8.29M7.84M8.15M21.28M28.81M

LENZ Therapeutics, Inc.

NASDAQ:LENZ

Intrinsic Alpha fair value

Locked

Current Price

$3.21

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.